What Ovarid Treats: Main Uses and Benefits

Ovarid, containing Megestrol Acetate, is commonly used to help with symptomatic relief and supportive therapeutic benefit in clinical situations dominated by severe metabolic depletion or hormone-driven disease progression. The medication is generally applied in contexts where additional support for managing distressing symptoms is considered relevant.

It is relevant across two primary therapeutic domains: providing nutritional support for patients experiencing severe wasting syndrome (cachexia) and profound loss of appetite (anorexia), and offering palliative management for specific advanced, recurrent, or metastatic cancers of the breast and endometrium. The medication helps address symptom clusters that may become intense or disruptive, such as involuntary weight loss and nutritional decline, and is applicable within clinical settings that involve acute or disruptive symptom patterns.

“The therapeutic support assists patients in coping more steadily with the challenging phases of their condition, particularly those involving metabolic stress.”

The overall benefit helps ease the overall burden of metabolic decline and supports general well-being and assists with maintaining functional stability.

Quick Fact: Symptomatic Management
Supports the patient's goal of increased food intake and weight stability during chronic, debilitating illness, which is relevant for patients with AIDS or cancer.

Regulatory References

1. Megestrol - StatPearls - NCBI Bookshelf - NIH

Who Can and Cannot Use Ovarid?

The population eligibility for Ovarid (Megestrol Acetate) is strictly defined by governmental regulatory authorities based on contraindications, existing health status, and age classification.

Adults receiving treatment for advanced breast or endometrial cancer, or those with anorexia/cachexia associated with AIDS, are the established populations for its use. Use for prophylaxis (prevention of weight loss) is not intended.

---

Mandatory Exclusions (Contraindications)

Population/Condition	Regulatory Status
Known or Suspected Pregnancy	Contraindicated (Women of childbearing potential must use effective contraception)
Hypersensitivity	Contraindicated (To Megestrol Acetate or any component)

---

Restrictions and Special Considerations

Pediatric use is not recommended as safety and effectiveness have not been established in children. Older adults should use Ovarid with caution due to a greater frequency of decreased organ function.

Caution is also required for patients with pre-existing conditions such as a history of thromboembolic disease, diabetes mellitus, impaired renal function, or impaired hepatic function. Use during lactation is not recommended; nursing should be discontinued.

The official regulatory profile for Ovarid (Megestrol Acetate) documents specific interactions categorized by their effect on exposure or therapeutic activity. Co-administration with Dofetilide is formally contraindicated according to official drug labeling due to a documented interaction risk.

The drug engages in pharmacokinetic interactions: Megestrol Acetate acts as an inducer of CYP3A4 metabolism, which leads to a significant decrease in the plasma exposure (AUC) of co-administered drugs that are substrates for this enzyme, such as Indinavir. For this combination, a higher dose of Indinavir should be considered to maintain adequate systemic levels. The official data also notes that the combination with Mavacamten should be avoided as it decreases Megestrol Acetate exposure via effects on CYP3A4.

A significant outcome-based interaction exists with the anticoagulant Warfarin, where Megestrol Acetate increases the effects of Warfarin, resulting in an officially documented rise in the International Normalized Ratio (INR). Close monitoring of INR is therefore required. Pharmacodynamic antagonism is also documented with Insulin and other antidiabetic agents. Because the progestin may impair glucose tolerance, patients with new-onset or pre-existing diabetes require close monitoring of blood glucose levels. Furthermore, combining Ovarid with agents like Etrasimod or Siponimod carries the risk of additive immunosuppressive effects. Regulatory studies confirmed no significant alteration in the exposure of Zidovudine or Rifabutin when co-administered. No mandatory timing separation rules or known food interactions are documented in the primary labeling.

Ovarid contains megestrol acetate, a synthetic progestin that acts primarily as an agonist at the progesterone receptor (PR). This engagement initiates multiple signaling cascades that result in its physiological effects.

---

Modulation of Gonadotropin Release

Ovarid acts within domains involving receptor-mediated signaling at the progesterone receptor. By binding to this receptor, the drug mimics the body's natural progesterone, primarily in the hypothalamus and pituitary gland. This action suppresses the signaling sequence that leads to the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus and, consequently, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary. The resulting physiological effect is a more regulated state in the reproductive axis, modulating the hormonal fluctuations associated with pre-ovulatory events.

---

Anti-Estrogenic and Receptor Cascade Effects

The drug also exerts anti-estrogenic properties by engaging mechanisms that influence feedback regulation within reproductive pathways. It can directly or indirectly reduce the concentration of estrogen receptors in target tissues like the uterus. By modifying early molecular steps in the estrogen signaling cascade, Ovarid results in a reduction of estrogen-mediated signaling intensity. This action modifies target tissue sensitivity to heightened hormonal stimulation, which shapes its overall effect profile.

Ovarid is defined by its official usage instructions, which specify the approved route of administration, distinct dosing regimens for its labeled uses, and specific procedural requirements for its various forms. These instructions outline the standard administration protocol.

Official Administration and Dosing

Usage Parameter	Requirement
Route of Administration	The medicine must be taken orally (PO).
Dosage Forms	Available as tablets (e.g., 20 mg, 40 mg, 160 mg) and oral suspension (e.g., 40 mg/mL and 125 mg/mL).
Breast Cancer Regimen	160 mg per day, typically administered as 40 mg four times a day (q.i.d.).
Endometrial Cancer Regimen	40 mg to 320 mg per day in divided doses.
AIDS-Related Anorexia/Cachexia	800 mg once daily (40 mg/mL suspension) OR 625 mg once daily (125 mg/mL suspension).

---

Administration Requirements

Duration of Use: For cancer treatment, a minimum of two months of continuous therapy is considered an adequate period for determining efficacy.

Suspension Preparation: The oral suspension container must be shaken well before each use.

Non-Interchangeability: The 125 mg/mL oral suspension concentration is not substitutable with the 40 mg/mL concentration on a milligram-per-milligram basis, requiring specific dose quantities for each form.

Tablet Use: For scored tablets, the break line is intended only to facilitate swallowing and is not intended to divide the tablet into equal doses.

Population Caution: Dose selection for older adult patients should be cautious, reflecting the increased likelihood of reduced hepatic, renal, or cardiac function. Safety and effectiveness in children have not been established.

Research Evidence / Overview of Studies for Ovarid

Evidence for Appetite Support and Wasting Syndrome (Cachexia)

Research has primarily focused on the study of Megestrol Acetate (the active component of Ovarid) in individuals experiencing severe loss of appetite and significant involuntary weight loss (known as cachexia). The evidence base for this area of study is largely derived from randomized controlled trials (RCTs) and subsequent systematic reviews. These studies were conducted during periods of increased symptom activity in adult populations with advanced conditions, particularly cancer and, historically, AIDS/HIV.

In these trials, research examined outcomes related to systemic or functional imbalance, such as changes in total body weight and patient-reported outcomes describing perceived discomfort related to food intake. Findings describe patterns observed in the studies related to changes in appetite and associated weight changes during the observed short-term periods (typically 4 to 12 weeks).

The evidence supporting broader, non-weight related outcomes is less developed. Findings were mixed across studies regarding how patient-reported experiences, such as overall quality of life, evolved in the observed populations.

Evidence for Management of Hormone-Sensitive Cancers

Megestrol Acetate was studied for use as a hormonal agent in the care of specific hormone-sensitive cancers, notably advanced breast cancer and advanced endometrial cancer. The research involved Phase II and Phase III clinical trials, focusing on patient groups with hormone-receptor positive tumors.

Studies monitored traditional oncology outcomes, primarily assessing the tumor response rate (the measured change in tumor size), the duration of any observed response, and the time until the disease showed signs of progression. Findings indicate that the agent was associated with periods of disease stability or observed tumor size changes in some patients.

What Remains Uncertain About the Research Evidence

Clinical trials have generally focused on short-term outcomes. Long-term effects are not fully established for the durability of appetite changes or sustained weight maintenance. The focus on weight gain and appetite means that evidence is limited for other outcomes reflecting daily functioning or activity level. The trials often excluded patients with high levels of physical activity or severe comorbidities, emphasizing that results apply only to the populations studied. Ongoing research continues to explore these gaps, but the overall evidence highlights what is known—and what is still uncertain—about the agent's observed patterns.

Common questions about Ovarid (FAQ)

---

Q: Is there a generic version of Ovarid available?

A: Ovarid's active ingredient is Megestrol Acetate. According to official information, generic formulations of Megestrol Acetate Tablets are available and have been determined by regulatory bodies to be therapeutically equivalent to the brand-name drug.

---

Q: Is Ovarid a medication that I have to take long-term?

A: The required duration for taking this medicine is determined by the specific medical problem being addressed. Official regulatory documents indicate that for some cancer treatments, a minimum of two months is needed to determine if the medicine is having an effect.

---

Q: What is the typical duration of treatment with Ovarid?

A: The duration of treatment is not fixed and depends on the specific condition a person is taking it for. For instance, in the management of advanced breast or endometrial cancer, official documents specify that treatment should continue for at least two months to adequately assess its efficacy.

---

Q: Can Ovarid affect the results of common blood tests?

A: Yes, official safety information indicates that Ovarid may potentially affect the results of certain lab tests. It has been documented to cause effects consistent with glucocorticoid activity and can cause changes in blood glucose (sugar) levels, which may be reflected in blood test results.

---

Q: How long does it typically take to start noticing the effects of Ovarid?

A: Clinical studies provide an overview of when effects were observed. For the purpose of appetite support, changes in body weight and patient-reported appetite were often tracked and reported in clinical trials over periods of 4, 8, and 12 weeks from the start of therapy.

---

Q: What happens if I forget to take Ovarid for one day?

A: Regulatory instructions describe a general approach for missed doses, which typically involves taking the dose on the same day. Official regulatory instructions include a specific caution that a double dose should generally not be taken if a full day has passed.

---

Q: Does Ovarid affect my ability to drive or operate machinery?

A: According to official regulatory documents, Megestrol Acetate has been stated to have no or a negligible influence on a person’s ability to drive or operate machinery.

---

Q: What should I do if a side effect of Ovarid seems minor but is bothersome?

A: General patient information found in regulatory sources emphasizes the importance of reviewing any side effects that continue or become bothersome with a healthcare professional.

---

Q: How quickly does Ovarid leave the system after the last dose?

A: Pharmacokinetic data from official sources describes the elimination rate of the active component. The mean plasma elimination half-life for Megestrol Acetate is highly variable, with a documented range that spans from approximately 10 to 120 hours.

---

Q: Why are there warnings about combining Ovarid with herbal products?

A: Official patient information emphasizes the need to disclose all products, including prescribed, over-the-counter, herbal, and complementary therapies, to a healthcare professional. This is because combining Ovarid with other substances carries a potential risk for drug-drug or drug-herb interactions.

---

Q: Can Ovarid be crushed or mixed with food if swallowing pills is difficult?

A: Regulatory documents describe that the tablets are typically administered by swallowing them whole with a glass of water. Regulatory information notes that for scored tablets, the break line is only to facilitate swallowing and is not meant to divide the tablet into equal doses. Manipulating tablets may alter drug exposure.

---

Q: Is Ovarid known to affect mental health or mood?

A: Yes, official regulatory documents list psychiatric reactions as potential adverse events. Specifically, side effects such as altered mood, depression, and confusion have been included in adverse event reporting, typically classified as common events.

---

Q: Does Ovarid interact with caffeine or high sugar intake?

A: Regulatory documents state that Megestrol Acetate is known to impair glucose tolerance and can cause a condition known as hyperglycemia (high blood sugar). Official patient information notes that monitoring of blood sugar may be necessary due to this effect.

---

Q: Is Ovarid suitable for people who have allergies to certain ingredients?

A: The medicine is formally contraindicated (strongly advised against) for patients who have a known history of hypersensitivity or an allergic reaction to Megestrol Acetate or any other component in its formulation.

---

Q: Are there any groups of people who are strongly advised not to use Ovarid?

A: Mandatory exclusions for the use of Ovarid include patients who are pregnant or have a known hypersensitivity to the drug. Regulatory warnings also advise special caution for individuals with a history of thromboembolic disease, diabetes mellitus, or impaired liver or kidney function.

Storage and Disposal Requirements for Ovarid (Megestrol Acetate)

The storage and disposal of Ovarid must adhere strictly to conditions outlined in official regulatory documents to maintain product integrity and ensure public safety.

Item	Official Regulatory Requirement
Storage Temperature	Tablets: Store at a temperature not exceeding 25 C. Suspension: Store at controlled room temperature (15 C to 30 C), protecting from heat.
Container Protection	Keep the medicine in the original package to protect contents from moisture and store in tightly closed containers.
Child Safety	Mandatory requirement to keep the product out of the sight and reach of children.
Disposal	Unused or expired Ovarid must be disposed of according to local regulations. It must not be thrown into wastewater or household trash.

Regulatory documents define a maximum storage temperature of 25 C for the tablets and require moisture protection to maintain stability. The medicine must be kept safely away from children. Final disposal must follow local guidelines to prevent environmental contamination.